1-20 of 31
Jue Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeted Delivery of IL-12 Via CD19-Modified Extracellular Vesicles Enhances CAR-T Cell Efficacy Against Lymphoma

Meijuan Huang, Lei Zhao, Dengju Li, Liang Huang, Jue Wang, Yuanyuan Zhang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6798.
https://doi.org/10.1182/blood-2023-180860
Published: 2023
Journal Articles

Heterogeneity and Differentiation Patterns of pDC Cells in pDC-AML: A Novel Perspective from Single-Cell RNA Sequencing

Xingcheng Yang, Juan Peng, Chunrui Li, Yicheng Zhang, Xia Mao, Jue Wang, Jia Wei
Journal: Blood
Blood (2023) 142 (Supplement 1): 1568.
https://doi.org/10.1182/blood-2023-190826
Published: 2023
Journal Articles

Phase 1 Dose Escalation Study of the Anti-CD7 CAR-T Therapy in Relapsed/Refractory T-Cell Acute Leukemia and Lymphoblastic Lymphoma

Jiali Cheng, Jue Wang, Xia Mao, Wei Mu, Shijia Sun, Xiaoxi Zhou, Liang Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6863.
https://doi.org/10.1182/blood-2023-184370
Published: 2023
Journal Articles

Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients

Zongcheng Li, Lei Zhao, Yuanyuan Zhang, Li Zhu, Wei Mu, Tong Ge, Jin Jin, Jiaqi Tan, Jiali Cheng, Jue Wang, Na Wang, Xiaoxi Zhou, Liting Chen, Zhilin Chang, Chen Liu, Bian Zhilei, Bing Liu, Lilin Ye, Yu Lan, Liang Huang, Jianfeng Zhou
Journal: Blood
Blood (2023) 142 (Supplement 1): 4851.
https://doi.org/10.1182/blood-2023-178624
Published: 2023
Journal Articles

CD19/CD22 CAR T-Cell Therapy Following Autologous Transplantation Is an Optimizing Strategy in Relapsed/Refractory Central Nervous System Lymphoma

Qiuxia Yu, Daizi Gang, Jue Wang, Liang Huang, Chunrui Li, Yicheng Zhang, Xiaoxi Zhou, Yang Cao
Journal: Blood
Blood (2023) 142 (Supplement 1): 6855.
https://doi.org/10.1182/blood-2023-180363
Published: 2023
Journal Articles

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Clinical Trials & Observations
Naval G. Daver, Monique Dail, Jacqueline S. Garcia, Brian A. Jonas, Karen W. L. Yee, Kevin R. Kelly, Norbert Vey, Sarit Assouline, Gail J. Roboz, Stefania Paolini, Daniel A. Pollyea, Agostino Tafuri, Joseph M. Brandwein, Arnaud Pigneux, Bayard L. Powell, Pierre Fenaux, Rebecca L. Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Cherie Green, Marion G. Ott, Wan-Jen Hong, Marina Y. Konopleva, Michael Andreeff
Journal: Blood
Blood (2023) 141 (11): 1265–1276.
https://doi.org/10.1182/blood.2022016362
Published: 2023
Includes: Supplemental data
Journal Articles

Allogeneic CAR-T Therapy Enabled By Base Editing of Lck to Resist Dasatinib Used to Prevent Rejection Mediated through Both T and NK in Host

Yuhang Cheng, Jiayuan Zhang, Xiaoqian Wang, Wenjie Dong, Xiaomin Yao, Yage Zhang, Juan Yang, Wei Mu, Jue Wang, Liang Huang, Guang Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 4556–4557.
https://doi.org/10.1182/blood-2022-169039
Published: 2022
Journal Articles

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Chunrui Li, Di Wang, Baijun Fang, Yongping Song, He Huang, Jianyong Li, Dehui Zou, Bing Chen, Jing Liu, Yujun Dong, Hanyun Ren, Kai Hu, Peng Liu, Xi Zhang, Jian-Qing Mi, Zhenyu Li, Kaiyang Ding, Jue Wang, Liting Chen, Aining Xu, Songbai Cai, Jingwen Zeng, Jingjing Guo, Hongyu Gui, Wen Wang, Lugui Qiu
Journal: Blood
Blood (2022) 140 (Supplement 1): 7435–7436.
https://doi.org/10.1182/blood-2022-166465
Published: 2022
Journal Articles

An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy

Sarah F. McGough, Natasha Shamas, Jue Wang, Mahmoud Jaber, Binay Swarup, Marie-Helene Blanchet Zumofen, Bertrand Lautié, Joana Parreira, Michael C. Wei, Ashwini Shewade
Journal: Blood
Blood (2022) 140 (Supplement 1): 3658–3660.
https://doi.org/10.1182/blood-2022-159640
Published: 2022
Journal Articles

Olverembatinib Based Therapy in Recurrent Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR/ABL Mutation

Qiuxia Lv, Qiuxia Yu, Yang Cao, Jue Wang, Yicheng Zhang, Gaoxiang Wang, Zhenya Hong, Li Meng
Journal: Blood
Blood (2022) 140 (Supplement 1): 11688–11689.
https://doi.org/10.1182/blood-2022-157416
Published: 2022
Journal Articles

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Chunrui Li, Di Wang, Yongping Song, Jianyong Li, He Huang, Bing Chen, Jing Liu, Kai Hu, Hanyun Ren, Xi Zhang, Zhenyu Li, Dehui Zou, Qingsong Yin, Lijuan Chen, Yongxian HU, Yong Xu, Qian Cheng, Yuelu Guo, Yujun Dong, Li Gao, Aining Xu, Songbai Cai, Wen Wang, Ming Wu, Jue Wang, Liting Chen, Jianfeng Zhou, Lugui Qiu
Journal: Blood
Blood (2021) 138 (Supplement 1): 547.
https://doi.org/10.1182/blood-2021-152576
Published: 2021
Journal Articles

SARS-CoV-2 infection induces the activation of tissue factor–mediated coagulation via activation of acid sphingomyelinase

Brief Report
Jue Wang, Usha R. Pendurthi, Guohua Yi, L. Vijaya Mohan Rao
Journal: Blood
Blood (2021) 138 (4): 344–349.
https://doi.org/10.1182/blood.2021010685
Published: 2021
Includes: Supplemental data
Journal Articles

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Di Wang, Jue Wang, Guang Hu, Wen Wang, Yi Xiao, Haodong Cai, Lijun Jiang, Li Meng, Yongkun Yang, Xiaoxi Zhou, Zhenya Hong, Zheng Yao, Min Xiao, Liting Chen, Xia Mao, Li Zhu, Jin Wang, Lugui Qiu, Chunrui Li, Jianfeng Zhou
Journal: Blood
Blood (2021) 137 (21): 2890–2901.
https://doi.org/10.1182/blood.2020008936
Published: 2021
Includes: Supplemental data
Journal Articles

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Chunrui Li, MD PhD, Jue Wang, MD PhD, Di Wang, MD PhD, Guang Hu, Yongkun Yang, Xiaoxi Zhou, MD PhD, Li Meng, MD PhD, Zhenya Hong, MD PhD, Liting Chen, PhD, Xia Mao, MD PhD, Min Xiao, MD PhD, Jianfeng Zhou, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 929.
https://doi.org/10.1182/blood-2019-128468
Published: 2019
Journal Articles

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

Naval G. Daver, MD, Jacqueline S Garcia, MD, Brian A Jonas, MD PhD, Kevin R Kelly, MD PhD, Sarit Assouline, MD, Joseph M Brandwein, MD, Pierre Fenaux, MD PhD, Rebecca L. Olin, MD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Arnaud Pigneux, Daniel A Pollyea, MD, Bayard L Powell, MD, Gail J. Roboz, MD, Agostino Tafuri, MD, Norbert Vey, MD PhD, Giuseppe Visani, MD, Karen W.L. Yee, MD, Monique Dail, PhD, Cherie Green, BS, Whitney P Kirschbrown, PharmD, PhD, Wan-Jen Hong, MD, Marion G Ott, MD PhD, Maika Onishi, MD, Jue Wang, PhD, Marina Y Konopleva, MD PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 229.
https://doi.org/10.1182/blood-2019-123711
Published: 2019
Journal Articles

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Barbara F. Eichhorst, MD, Peter Hillmen, MD PhD, James D'Rozario, MBBS, FRACP, FRCPA, Sarit Assouline, MD, Carolyn Owen, MD, Tadeusz Robak, MD, Javier de la Serna, MD PhD, Ulrich Jaeger, MD, Guillaume Cartron, Marco Montillo, MD, Nicole Lamanna, MD, Su Young Kim, MD PhD, Jenny Wu, MS, Yanwen Jiang, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Arnon P Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 355.
https://doi.org/10.1182/blood-2019-123930
Published: 2019
Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Arnon P Kater, MD PhD, Jenny Qun Wu, MS, Julie Dubois, Christopher R Bolen, PhD, Zoe J Assaf, PhD, Peter Hillmen, MD PhD, Barbara F. Eichhorst, MD, Eric F Eldering, PhD, Thomas J. Kipps, MD PhD, Anton W Langerak, PhD, Clemens Mellink, PhD, Anne-Marie Van Der Kevie-Kersemaekers, PhD, Carolyn Owen, MD, Brenda J Chyla, PhD, Elizabeth A Punnoose, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Yanwen Jiang, PhD, John F. Seymour, MBBS, PhD FRACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 356.
https://doi.org/10.1182/blood-2019-123678
Published: 2019
Journal Articles

Alterations in Sphingomyelin Metabolism Influences Tissue Factor Procoagulant Activity and the Release of TF-Positive Microvesicles

Jue Wang, PhD, Usha Pendurthi, PhD, L. Vijaya Mohan Rao, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1103.
https://doi.org/10.1182/blood-2019-125933
Published: 2019
Journal Articles

Acid sphingomyelinase plays a critical role in LPS- and cytokine-induced tissue factor procoagulant activity

Jue Wang, Usha R. Pendurthi, L. Vijaya Mohan Rao
Journal: Blood
Blood (2019) 134 (7): 645–655.
https://doi.org/10.1182/blood.2019001400
Published: 2019
Includes: Supplemental data
Journal Articles

SHP-1 As a Negative Regulator of FLT3 Associated Aberrant Signaling and a New Potential Target to FLT3-ITD Mutation

Tongjuan Li, MD PhD, Dan Li, Lei Zhao, MD, Jue Wang, MD PhD, Zhen Shang, MD PhD, Yicheng Zhang, MD PhD, Liang Huang, MD PhD, Jianfeng Zhou, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4051.
https://doi.org/10.1182/blood-2018-99-115793
Published: 2018